Table 2. Results of pairwise and network meta-analyses for the rate of symptomatic relief.
| Dex30 | 1.23(0.9, 1.68);p-value: 0.2 | NA | NA | NA | NA | NA | NA | 5.09(3.53, 7.35);p-value < 0.00001 | NA | NA | NA |
| 1.23(0.71,2.13);p-value: 0.46 | Dex60 | NA | NA | NA | NA | NA | NA | 4.15(2.88, 6);p-value < 0.00001 | NA | NA | NA |
| 1.48(0.75,2.95);p-value: 0.26 | 1.21(0.61,2.41);p-value: 0.59 | Eso20 | 0.89(0.68, 1.15);p-value: 0.37 | NA | NA | NA | NA | 3.46(2.46, 3.87);p-value < 0.00001 | NA | NA | NA |
| 1.38(0.68,2.81);p-value: 0.69 | 1.13(0.55,2.29);p-value: 0.74 | 0.93(0.65,1.34);p-value: 0.69 | Eso40 | NA | NA | NA | NA | 3.55(2.32, 5.44);p-value < 0.00001 | NA | NA | NA |
| 1.52(0.54,4.26);p-value: 0.43 | 1.24(0.44,3.48);p-value: 0.68 | 1.03(0.41,2.58);p-value: 0.95 | 1.10(0.43,2.82);p-value: 0.84 | Lan15 | 1.09(0.77, 1.54);p-value: 0.63 | NA | NA | 3.34(1.63, 6.83);p-value:0.0009 | NA | NA | NA |
| 1.66(0.59,4.64);p-value: 0.34 | 1.35(0.48,3.79);p-value: 0.57 | 1.12(0.44,2.81);p-value: 0.81 | 1.20(0.47,3.07);p-value: 0.7 | 1.09(0.61,1.93);p-value: 0.77 | Lan30 | NA | NA | 3.07(1.5, 6.28);p-value: 0.002 | NA | NA | NA |
| 1.99(1.00,3.96);p-value: 0.05 | 1.62(0.81,3.23);p-value: 0.17 | 1.34(0.80,2.23);p-value: 0.27 | 1.44(0.84,2.48);p-value: 0.18 | 1.30(0.52,3.28);p-value: 0.57 | 1.20(0.48,3.02);p-value: 0.7 | Ome10 | 0.36(0.16, 0.81);p-value: 0.01 | 2.52(1.9, 3.35);p-value < 0.00001 | NA | NA | NA |
| 1.05(0.53,2.10);p-value: 0.89 | 0.86(0.43,1.71);p-value: 0.67 | 0.71(0.42,1.19);p-value: 0.2 | 0.76(0.44,1.32);p-value: 0.33 | 0.69(0.27,1.74);p-value: 0.44 | 0.63(0.25,1.60);p-value: 0.33 | 0.53(0.37,0.75);p-value: 0.0005 | Ome20 | 4.93(2.94, 8.26);p-value < 0.00001 | NA | NA | NA |
| 5.09(2.84,9.13);p-value < 0.00001 | 4.15(2.32,7.45);p-value < 0.00001 | 3.43(2.39,4.93);p-value < 0.00001 | 3.69(2.46,5.53);p-value < 0.00001 | 3.34(1.43,7.80);p-value < 0.0053 | 3.07(1.32,7.17);p-value < 0.0092 | 2.56(1.78,3.69);p-value < 0.00001 | 4.85(3.34,7.04);p-value < 0.00001 | Pla | 0.38(0.28, 0.51);p-value < 0.00001 | 0.19(0.05, 0.78);p-value: 0.02 | 0.58(0.32, 1.04);p-value: 0.07 |
| 1.80(0.88,3.69);p-value: 0.11 | 1.47(0.72,3.01);p-value: 0.31 | 1.22(0.70,2.10);p-value: 0.48 | 1.31(0.74,2.33);p-value: 0.35 | 1.18(0.46,3.04);p-value: 0.73 | 1.09(0.42,2.79);p-value: 0.86 | 0.91(0.52,1.57);p-value: 0.74 | 1.72(0.99,2.99);p-value: 0.054 | 0.35(0.24,0.53);p-value < 0.00001 | Rab10 | 0.98(0.49, 1.94);p-value: 0.95 | 1.33(0.76, 2.34);p-value: 0.32 |
| 1.23(0.52,2.91);p-value: 0.64 | 1.00(0.42,2.38);p-value: 1 | 0.83(0.40,1.71);p-value: 0.62 | 0.89(0.42,1.89);p-value: 0.76 | 0.81(0.28,2.33);p-value: 0.7 | 0.74(0.26,2.14);p-value: 0.57 | 0.62(0.30,1.28);p-value: 0.2 | 1.17(0.56,2.44);p-value: 0.68 | 0.24(0.13,0.46);p-value < 0.00001 | 0.68(0.35,1.32);p-value: 0.26 | Rab20 | NA |
| 2.64(1.08,6.43);p-value: 0.03 | 2.15(0.88,5.25);p-value: 0.09 | 1.78(0.83,3.81);p-value: 0.14 | 1.91(0.87,4.19);p-value: 0.11 | 1.73(0.59,5.11);p-value: 0.32 | 1.59(0.54,4.70);p-value: 0.4 | 1.33(0.62,2.85);p-value: 0.46 | 2.51(1.16,5.42);p-value: 0.019 | 0.52(0.26,1.02);p-value: 0.064 | 1.46(0.75,2.84);p-value: 0.27 | 2.14(0.88,5.20);p-value: 0.093 | Rab5 |
Results of pairwise meta-analyses were listed in right upper triangles and results of network meta-analyses were listed in left lower triangles. Rab 5: Rabeprazole 5 mg; Rab 10: Rabeprazole 10 mg; Rab 20: Rabeprazole 20 mg; Pla: Placebo; Dex 30: Dexlansoprazole 30 mg; Dex 60: Dexlansoprazole 60 mg; Ome 10: Omeprazole 10 mg; Ome 20: Omeprazole 20 mg; Lan 15: Lansoprazole 15 mg; Lan 30: Lansoprazole 30 mg; Eso 20: Esomeprazole 20 mg; Eso 40: Esomeprazole 40 mg. The number which was painted by a style of overstriking indicated there was a significant difference between two treatments.